Table 1.
Baseline Characteristics of the enrolled patients.
| Variable | Total (n = 41) |
|---|---|
| Age, median years (IQR) | 61 (47–65) |
| Male | 27 (66) |
| Charlson's comorbidity index, median (IQR) | 4 (2–5) |
| Hypertension | 9 (22) |
| Diabetes mellitus | 8 (20) |
| Solid cancer | 3 (7) |
| Chronic kidney diseases | 9 (22) |
| Chronic lung disease | 1 (2) |
| Hematologic malignancy | 29 (70) |
| Acute myeloid leukemia | 8 (20) |
| Acute lymphoblastic leukemia | 4 (10) |
| Myelodysplastic syndrome | 3 (7) |
| Hodgkin's lymphoma | 1 (2) |
| Non-Hodgkin's lymphoma | 15 (37) |
| Solid organ transplantation | 12 (30) |
| Kidney transplantation | 9 (22) |
| Liver transplantation | 2 (5) |
| Lung transplantation | 1 (2) |
| Bone marrow transplantation | 14 (34) |
| Allogenic | 9 (22) |
| Autologous | 5 (12) |
| Days since transplantation, median (IQR) | 481 (181–4252) |
| B-cell depleting therapya | 10 (24) |
| Before COVID-19 | 4 (10) |
| After COVID-19 | 4 (10) |
| Before and after COVID-19 | 2 (5) |
| T-cell depleting therapyb | 4 (10) |
| Initial Severity | |
| Asymptomatic | 23 (56) |
| Mild | 8 (20) |
| Moderate | 6 (15) |
| Severe | 4 (10) |
| Vaccination status | |
| None | 12 (30) |
| Partial (1- or 2-dose) | 15 (38) |
| Completion of primary series (3-dose) | 14c (34) |
| Subvariants | |
| Omicron BA.1. | 7 (17) |
| Omicron BA.2. | 33 (80) |
| Undetermined | 1 (2) |
| COVID-19-specific treatment | 39 (95) |
| Remdesivir | 37 (90) |
| Ritonavir/nirmatrelvir | 2 (5) |
| Dexamethasone | 11 (27) |
| Tocilizumab | 4 (10) |
| Baricitinib | 5 (12) |
| Culture positivity | 102/142 (72) |
| Numbers of sample, median (IQR) | 3 (3–4) |
| Days of first sample after diagnosis, median (IQR) | 3 (1–12) |
| Days from last vaccination to infection, median (IQR)d | 99 (66.5–176) |
NOTE. Data are presented as number of patients (%) unless otherwise indicated.
9 patients received rituximab, and 1 patient received epocoritamab. 2 patients received rituximab to treat antibody-mediated rejection, while remaining 8 patients received B-cell depleting therapy to treat non-Hodgkin's lymphoma.
2 patients received anti-thymoglobulin therapy after diagnosis of COVID-19 to treat T-cell- mediated rejection and 1 patient received anti-thymoglobulin therapy as premedication for bone marrow transplantation after diagnosis of COVID-19. These 3 patients also received rituximab. One patient received basiliximab as premedication for lung transplantation before COVID-19.
None of the patients received a booster dose of COVID-19 vaccine.
One patient (partially vaccinated) did not remember the exact date of vaccination.